Evommune, Inc. (EVMN) is a Palo Alto, California-based clinical-stage biotechnology company developing oral and injectable therapies that target key drivers of chronic inflammatory diseases, with programs in chronic spontaneous urticaria, atopic dermatitis, ulcerative colitis, migraine and, more recently, rheumatoid arthritis. The company has no approved products and generates no product revenue, making it a binary, catalyst-driven story.
Shares changed hands at $7.16 in midday trading Thursday, up $0.28, or 4.07%, from the prior session's close of $6.88. The direction is unambiguously higher, though the gain only partly offsets a sharp six-session retreat that had knocked roughly 20% off the share price. No verified company-specific catalyst was identified for the session; the advance looks technical in nature, driven by buyers stepping in after a steep decline rather than by new information.
No verified news or fundamental catalyst found in company disclosures, regulatory filings, newswire activity, analyst coverage or sector news flow on Thursday. The most recent material events remain the third-quarter report on Nov. 12 and last week's round of analyst price-target reductions, both of which predate today's move and were followed by declines, not gains.
The most plausible technical explanation is a mechanical rebound after a punishing stretch. From the Nov. 11 close of $8.62, the stock fell for five of the next six sessions, touching $6.74 on Nov. 18 — within 36% of its 52-week low of $4.94. Short interest of roughly 3.4 million shares, or about 8.2% of shares outstanding, is consistent with short covering adding fuel to intraday bounces of this size. Liquidity is also thin: the float is roughly 27 million shares for a company with around $296 million of market value, so modest order flow can move the tape several percent. Context matters here — this stock's average absolute daily move over the past 89 sessions is roughly 3.9%, and 36 of those sessions produced a move equal to or larger than today's. A 4% session is routine for it.
Participation has been unremarkable. Turnover Thursday ran well below the heavy volume seen during last week's earnings-related flush, when more than 1.1 million shares traded in a single session against a three-month average of roughly 840,000 shares. That gap argues for repositioning rather than institutional accumulation.
The move also diverged from the tape. The S&P 500 was down about 1%, small caps were off roughly 1.4%, and the major biotech ETFs were flat to slightly lower, with one broad biotech benchmark fractionally positive. Evommune's gain was therefore idiosyncratic; there was no sector tailwind to lean on.
Technically, the stock remains in a downtrend. It trades below its 50-day moving average near $7.26 and far below its 200-day average near $17, and it briefly spiked to $7.39 before fading. Reclaiming the 50-day line would be the first sign of a durable shift in trend.
The score runs from 0 to 100, where 0 means no meaningful news and a move entirely normal for the stock, and 100 means transformative news paired with an extreme, rare price move. Evommune earns 8 out of 100. There was no verified news of any kind, so the fundamental component is minimal; nothing material changed in the company's pipeline, balance sheet or analyst coverage. The price move was also unexceptional against the stock's own history, at roughly 1.05 times its typical daily swing, with dozens of larger moves logged in the past 89 sessions. With weak news and an ordinary move, both components are low.
Attention now turns to the company's fourth-quarter and full-year 2026 results, expected in the first quarter of 2027. Investigators will watch for updates on the migraine Phase 2b trial of EVO756 and on EVO301, which is slated to enter a Phase 2b study in atopic dermatitis around mid-2027. The in-licensed VAV1 degrader EVO570 is expected to begin Phase 1 dosing in the first quarter of 2027, with healthy-volunteer and biomarker data anticipated mid-year, and a rheumatoid arthritis Phase 2 program planned for the second half of 2027.
Analyst coverage remains constructive in aggregate, though targets have been reset sharply lower since the summer. Key risks include further dilution, since the company remains pre-revenue and burned roughly $91 million in the past four quarters, and the long gap until the next patient data readout. Management has guided to a cash runway into the second half of 2029, which limits near-term financing pressure.
Tickeron's Trending AI Robots page highlights the strategies currently working hardest in live market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers are surfaced in this curated section, which is refreshed as market conditions evolve. Bots differ widely by strategy logic, timeframe, performance metrics and the symbols they trade. Reviewing this list can help traders see which approaches are keeping pace with the current tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for EVMN moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 2 instances where the indicator moved out of the overbought zone. In 2 of the 2 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 11 of 11 cases where EVMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EVMN broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EVMN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on EVMN as a result. In 12 of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for EVMN just turned positive on October 19, 2026. Looking at past instances where EVMN's MACD turned positive, the stock continued to rise in 4 of 6 cases over the following month. The odds of a continued upward trend are 67%.
EVMN moved above its 50-day moving average on November 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EVMN crossed bullishly above the 50-day moving average on November 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +12.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVMN advanced for three days, in 33 of 41 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.869) is normal, around the industry mean (3.596). P/E Ratio (-0.562) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (34.014) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. EVMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology